Risk of hospitalization and mortality after breakthrough SARS-CoV-2 infection by vaccine type and previous SARS-CoV-2 infection utilizing medical claims data
Kshirsagar, M.; Mukherjee, S.; Nasir, M.; Becker, N.; Lavista Ferres, J. M.; Richardson, B.
Show abstract
We compare the risks of hospitalization (n=1121) and mortality (n=138) in a cohort of 17,881 breakthrough SARS-CoV-2 infections for the Pfizer, Moderna and Janssen vaccines for those with and without SARS-CoV-2 infections prior to vaccination. Cox regression analysis results in a lower hazard ratio for breakthroughs receiving the Moderna vaccine, but a significantly higher hazard ratio for breakthroughs receiving the Janssen vaccine, as compared to breakthroughs who got the Pfizer vaccine. Further, the risk of hospitalization (P<0.001) and death (P<0.05) were lower among breakthroughs who had a SARS-CoV-2 infection prior to vaccination, independent of age, sex, comorbidities, and vaccine type. NoteWe do not study the role of natural immunity in SARS-CoV-2 infections, as our cohort does not contain unvaccinated individuals.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Real-world comparative effectiveness of mRNA-1273 and BNT162b2 vaccines among immunocompromised adults in the United States 96%
- Effectiveness of second booster compared to first booster and protection conferred by previous SARS CoV-2 infection against symptomatic Omicron BA.2 and BA.4/5 in France 96%
- Effectiveness of vaccines in preventing hospitalization due to COVID-19: A multicenter hospital-based case-control study, Germany, June 2021 to January 2022 95%
Similar papers in this journal
- Effectiveness of COVID-19 vaccines against hospitalization and death in Canada: A multiprovincial test-negative design study 95%
- Immunogenicity of a third dose of BNT162b2 to ancestral SARS-CoV-2 & Omicron variant in adults who received two doses of inactivated vaccine 94%
- Coronavirus Disease 2019 (COVID-19) Vaccine Boosting in Persons Already Protected by Natural or Vaccine-Induced Immunity 94%
Similar papers in this journal
- Comparative Effectiveness of the Bivalent (Original/Omicron BA.4/BA.5) mRNA COVID-19 Vaccines mRNA-1273.222 and BNT162b2 Bivalent in Adults With Underlying Medical Conditions in the United States 94%
- Durability of protection post-primary COVID-19 vaccination in the US: matched case-control study 94%
- Safety and efficacy of two immunization schedules with an inactivated SARS-CoV-2 vaccine in adults. A randomized non-inferiority clinical trial 93%
Similar papers in this journal
- Real-world effectiveness of Ad26.COV2.S adenoviral vector vaccine for COVID-19 95%
- Durability of the immune response to a third BNT162b2 dose; five months follow-up 94%
- Safety of the BNT162b2 mRNA COVID-19 Vaccine in Children below 5 Years (CoVacU5) – an Investigator-Initiated Retrospective Cohort Study 94%
Similar papers in this journal
- Comparative single-dose mRNA and ChAdOx1 vaccine effectiveness against SARS-CoV-2, including early variants of concern: a test-negative design, British Columbia, Canada 95%
- Effectiveness of mRNA COVID-19 vaccines and hybrid immunity in preventing SARS-CoV-2 infection and symptomatic COVID-19 among adults in the United States 94%
- Population-level relative effectiveness of the COVID-19 vaccines and the contribution of naturally acquired immunity 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.